Active	Status	Sponsor type	Region	Phase	Filter
12 Active 0 Inactive 12 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

12 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Sheth, Veeral
INSITE-DME, NCT05610319: Treat & Extend Versus Fixed Dosing with Faricimab for Management of Diabetic Macular Edema: a Pragmatic, Multi-center, Open-label, Randomized, Controlled Trial	Active, not recruiting	4	446	Europe, Canada, US, RoW	Faricimab	McMaster University, Hoffmann-La Roche	Diabetic Macular Edema	12/26	12/26
DIAMOND-1, NCT05066997 / 2021-005173-95: Pivotal Study of OCS-01 Eye Drops in Subjects with Diabetic Macular Edema	Recruiting	2/3	497	US	Dexamethasone ophthalmic suspension (OCS-01), Dexamethasone, Vehicle, Placebo	Oculis, ICON plc	Diabetic Macular Edema	06/26	06/26
SIGLEC, NCT05839041: A Multiple Dose Study of AVD-104 for Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)	Active, not recruiting	2	300	US	AVD-104, Avacincaptad	Aviceda Therapeutics, Inc.	Geographic Atrophy of the Macula, Macular Degeneration	09/25	09/26
PRISM, NCT05197270: 4D-150 in Patients with Neovascular (Wet) Age-Related Macular Degeneration	Recruiting	1/2	215	US	4D-150 IVT, Aflibercept IVT	4D Molecular Therapeutics	Neovascular (Wet) Age-Related Macular Degeneration	11/25	11/26
NCT05643118: Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration	Recruiting	1	42	US	OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA), OLX10212	Olix Pharmaceuticals, Inc., Trial Runners, LLC	Neovascular Age-related Macular Degeneration	11/24	12/24
i-SIGHT, NCT05447650: Microcurrent Stimulation Therapy for Nonexudative Age-related Macular Degeneration	Active, not recruiting	N/A	95	US	i-Lumen(TM) AMD, i-Lumen(TM) AMD Sham	i-Lumen Scientific, Inc.	Age-Related Macular Degeneration, Dry Age-related Macular Degeneration, Nonexudative Age-related Macular Degeneration	06/25	06/25
Kirby, BreAnne
Tejas, NCT05387837: Safety, Tolerability and PK of Subcutaneous D-4517.2 in Subjects With Wet AMD or DME	Active, not recruiting	2	50	US	D-4517.2, aflibercept	Ashvattha Therapeutics, Inc.	Neovascular Age-related Macular Degeneration, Diabetic Macular Edema	11/24	12/24
PRISM, NCT05197270: 4D-150 in Patients with Neovascular (Wet) Age-Related Macular Degeneration	Recruiting	1/2	215	US	4D-150 IVT, Aflibercept IVT	4D Molecular Therapeutics	Neovascular (Wet) Age-Related Macular Degeneration	11/25	11/26
NCT05643118: Evaluation of OLX10212 in Patients With Neovascular Age-related Macular Degeneration	Recruiting	1	42	US	OLX10212 is a cell penetrating asymmetric small interference RNA (cp-asiRNA), OLX10212	Olix Pharmaceuticals, Inc., Trial Runners, LLC	Neovascular Age-related Macular Degeneration	11/24	12/24
NEAMES, NCT02988895: Episcleral Brachytherapy for the Treatment of Wet AMD	Active, not recruiting	N/A	11	US	episcleral brachytherapy, Strontium 90	Salutaris Medical Devices, Inc.	Macular Degeneration, Choroidal Neovascularization	05/23	05/25
i-SIGHT, NCT05447650: Microcurrent Stimulation Therapy for Nonexudative Age-related Macular Degeneration	Active, not recruiting	N/A	95	US	i-Lumen(TM) AMD, i-Lumen(TM) AMD Sham	i-Lumen Scientific, Inc.	Age-Related Macular Degeneration, Dry Age-related Macular Degeneration, Nonexudative Age-related Macular Degeneration	06/25	06/25
Barcewicz, Maggie
i-SIGHT, NCT05447650: Microcurrent Stimulation Therapy for Nonexudative Age-related Macular Degeneration	Active, not recruiting	N/A	95	US	i-Lumen(TM) AMD, i-Lumen(TM) AMD Sham	i-Lumen Scientific, Inc.	Age-Related Macular Degeneration, Dry Age-related Macular Degeneration, Nonexudative Age-related Macular Degeneration	06/25	06/25